证券代码：688319 证券简称：欧林生物 公告编号：2025-047 近期，成都欧林生物科技股份有限公司(以下简称"公司")"重组多重耐药金黄色葡萄球菌疫苗研制与产业 化"项目入选四川省2025年第二批省级科技计划，公司于2025年9月19日收到政府补助款项共计人民币 464万元，其中324.8万元为公司所获政府补助；其余139.2万元为项目合作单位所获政府补助。本次收到 的政府补助将全部计入公司专项应付款科目，并按照相关规定根据项目后续完成及验收情况进行相应会 计处理。公司所获政府补助324.8万元均为与收益相关的政府补助。 二、补助的类型及对上市公司的影响 根据《企业会计准则第16号一一政府补助》等有关规定，公司上述获得的政府补助属于与收益相关的政 府补助。由于相关政府补助项目存在验收条件，需在满足相关条件后才能计入当期损益，因此尚无法确 定上述政府补助对公司本年度及之后年度利润产生的影响。上述政府补助未经审计，具体的会计处理以 及对公司2025年度以及之后年度损益的影响最终以会计师年度审计确认后的结果为准。敬请投资者注意 投资风险。 特此公告。 成都欧林生物科技股份有限公司董事会 成都欧林生物科技股份 ...

Core Viewpoint - The company has decided to temporarily use part of its idle raised funds, not exceeding 80 million RMB, to supplement its working capital for a period not exceeding 12 months, ensuring that this does not affect the normal operation of the fundraising investment projects [10][17][18]. Group 1: Meeting Resolutions - The sixth session of the board of supervisors held its 25th meeting on September 19, 2025, and approved the proposal to use part of the idle raised funds to temporarily supplement working capital with unanimous consent [1][2]. - The sixth session of the board of directors held its 30th meeting on September 19, 2025, and also approved the proposal to open a temporary supplementary fund account for managing the raised funds [4][5]. Group 2: Fund Usage Details - The company plans to use the idle raised funds for a maximum of 80 million RMB to supplement working capital, with the usage period starting from the board resolution date and lasting no more than 12 months [10][14]. - As of September 18, 2025, the company has cumulatively used 696.73 million RMB of the raised funds, with a remaining balance of 106.70 million RMB [11]. Group 3: Previous Fund Returns - The company previously approved the use of up to 100 million RMB of idle raised funds to supplement working capital, with 13 million RMB returned early on March 20, 2025, and the remaining 87 million RMB returned by September 18, 2025 [7][8][12]. Group 4: Justification for Fund Usage - The decision to use idle raised funds is aimed at improving fund utilization efficiency and reducing financial costs, with an estimated reduction in interest expenses of 2.4 million RMB based on the current loan market rate [16][19].

证券日报网讯 9月19日晚间，欧林生物发布公告称，近期，成都欧林生物科技股份有限公司（以下简 称"公司"）"重组多重耐药金黄色葡萄球菌疫苗研制与产业化"项目入选四川省2025年第二批省级科技计 划，公司于2025年9月19日收到政府补助款项共计人民币464万元，其中324.8万元为公司所获政府补 助；其余139.2万元为项目合作单位所获政府补助。 （文章来源：证券日报） ...

9月19日欧林生物大宗交易一览 证券时报·数据宝统计显示，欧林生物今日收盘价为26.80元，下跌1.43%，日换手率为1.54%，成交额为 1.71亿元，全天主力资金净流入284.67万元，近5日该股累计下跌2.37%，近5日资金合计净流入7972.38 万元。 两融数据显示，该股最新融资余额为3.59亿元，近5日增加6384.40万元，增幅为21.66%。 据天眼查APP显示，成都欧林生物科技股份有限公司成立于2009年12月11日。注册资本40593.36万人民 币。（数据宝） 欧林生物9月19日大宗交易平台共发生2笔成交，合计成交量28.80万股，成交金额656.06万元。成交价格 均为22.78元，相对今日收盘价折价15.00%。 进一步统计，近3个月内该股累计发生7笔大宗交易，合计成交金额为2618.11万元。 | 成交量 | 成交金额 | 成交价 格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万 | （万元） | | 溢价（%） | | | | 股） | | （元） | | | | | 20.00 | ...

Group 1 - Watson Bio (300142.SZ) announced that its subsidiaries, Beijing Watson Innovation Biotechnology Co., Ltd., Yunnan Vaccine Laboratory Co., Ltd., and Yuxi Watson Biotechnology Co., Ltd., have jointly developed a freeze-dried varicella-zoster virus mRNA vaccine in collaboration with Fudan University and Shanghai Blue Magpie Biopharmaceutical Co., Ltd. [1] - The company has applied for clinical trials with the National Medical Products Administration and has recently received the "Acceptance Notice" [1]

人民财讯9月19日电，沃森生物(300142)9月19日公告，公司子公司北京沃森创新生物技术有限公司、云 南疫苗实验室有限公司、玉溪沃森生物技术有限公司联合复旦大学、上海蓝鹊生物医药有限公司联合研 发的冻干带状疱疹病毒mRNA疫苗向国家药品监督管理局申请临床试验，并于近日获得受理通知书。 转自：证券时报 ...

Group 1 - The core point of the article is that Watson Bio's subsidiary has had its clinical trial application for a freeze-dried herpes zoster virus mRNA vaccine accepted [1] Group 2 - The acceptance of the clinical trial application indicates progress in the development of innovative vaccine technology within the company [1] - This development could potentially enhance the company's position in the biopharmaceutical industry, particularly in the vaccine segment [1] - The mRNA vaccine technology is gaining traction globally, which may lead to increased interest and investment in similar projects [1]

昭衍新药（603127）(06127)发布公告，于2025年9月19日(交易时间后)，集团成员公司昭衍(苏州)新药刚 与工商银行订立协议，认购两项工商银行理财产品合共人民币4000万元，且连同公告日期仍未赎回的该 等工商银行理财产品合计投资总额为人民币4.1亿元。 ...

Core Insights - The fifth China Biopharmaceutical Quality Control Conference highlighted the National Medical Products Administration's (NMPA) comprehensive reform of drug regulation, aimed at enhancing review and approval quality and efficiency, thereby stimulating innovation in the biopharmaceutical sector [1] Regulatory Developments - The NMPA plans to fully implement the State Council's opinions on deepening drug and medical device regulatory reforms to promote high-quality development in the pharmaceutical industry [1] - Future reforms will focus on improving the review and approval system, enhancing regulatory frameworks, and addressing clinical needs [1] Industry Growth - Among the 56 innovative drugs approved for market by 2025, 18 are biopharmaceutical products, indicating a significant presence of biopharmaceuticals in the innovation pipeline [1] - The NMPA aims to support the development of advanced therapeutic drugs and encourage companies to integrate into international innovation and supply chains, promoting high-quality growth in China's biopharmaceutical industry [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.9% on September 19, with Kanghong Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3820.09, down 0.3%, while the Shenzhen Component Index closed at 13070.86, down 0.04% [1] Stock Performance - Notable gainers included: - Aopumai (688293) with a closing price of 53.41, up 1.71% on a trading volume of 34,700 shares and a turnover of 189 million yuan [1] - Kexing Pharmaceutical (688136) closed at 41.88, up 1.70% with a trading volume of 45,300 shares and a turnover of 189 million yuan [1] - Significant decliners included: - Kanghong Pharmaceutical (002773) which fell 6.09% to a closing price of 37.00, with a trading volume of 94,100 shares and a turnover of 355 million yuan [2] - Changchun High-tech (000661) decreased by 3.91% to 125.22, with a turnover of 1.674 billion yuan [2] Capital Flow - The biopharmaceutical sector saw a net outflow of 999.7 million yuan from institutional investors, while retail investors had a net inflow of 914 million yuan [2] - The table of capital flow indicates that: - Changchun High-tech had a net inflow of 67.986 million yuan from institutional investors [3] - Kanghua Biological (300841) experienced a net inflow of 11.825 million yuan from institutional investors [3]